About Us Careers Contact Us

Home
Products
Isotope Labeled Active Pharmaceutical Ingredients (APIs)
Bictegravir-[13C,d2,15N]

Inquiry List

* Name:
* Phone:
* Service & Products of Interested: [Isotope Labeled Active Pharmaceutical Ingredients (APIs)] Bictegravir-[13C,d2,15N]
Project Description:
* Quantity
* Email:
* Organization We recommend you to leave us your work email address so that we can serve you better. Please leave your organization information here if you don't have a work email address.
* Verification Code:

Our Highlights

Optimal Prices
Buying products on this site guarantees the best price
Flexible Batches
Flexible batch size to meet different needs of global customers
Prompt Delivery
Warehouses in multiple cities to ensure timely delivery
Quality Assurance
Strict process parameter control to ensure product quality
One-to-one Customization
One-to-one custom synthesis for special structural needs

Application Area

Environmental

Stable isotope-labeled compounds are used as environmental pollutant standards for the detection of air, water, soil, sediment and food.

Clinical diagnostic

In addition to treating various diseases, isotopes are used for imaging, diagnosis, and newborn screening.

Organic Chemistry

Small molecule compounds labeled with stable isotopes can be used as chemical reference for chemical identification, qualitative, quantitative, detection, etc. Various types of NMR solvents can be used to study the structure, reaction mechanism and reaction kinetics of compounds.

Metabolic Research

Stable isotope labeling allows researchers to study metabolic pathways in vivo in a safe manner.

Bictegravir-[13C,d2,15N]

Inquiry

General Information
Catalog: BLP-003458
Molecular Formula: C20[13C]H16D2F3N2[15N]O5
Molecular Weight: 453.38

Chemical Structure

Description	Labelled analog of Bictegravir. Bictegravir is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM for strand transfer activity. Bictegravir is a drug of the integrase inhibitor class that was copied from Dolutegravir by scientists at Gilead Sciences. Bictegravir also inhibits HIV-1 viral infection in MT-2 and MT-4 cells, CD4+ T cells, and macrophages (EC50s = 1.5, 2.5, 1.5, and 6.6 nM, respectively) without exhibiting cytotoxicity (CC50s = 10.3, 3.7, 13, and 29.8 μM, respectively). In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection.
Synonyms	(2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-((2,4,6-trifluorophenyl)methyl-13C-d2)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide-N-15N
Related CAS	1611493-60-7 (unlabelled)
Purity	> 98%